Merck Pays $2.75bn To Access VelosBio’s ROR1-Targeting ADCs
Private Biotech Raised $137m In Venture Capital In July
Merck continues its cancer deal streak, purchasing a pipeline of antibody-drug conjugates and bispecific antibodies against receptor tyrosine kinase-like orphan receptor 1 (ROR1).
